A number of major banks reported their second quarter 2024 earnings results on Friday. These include JPMorgan Chase & Co. (NYSE: JPM), Wells Fargo (NYSE: WFC), and Citigroup (NYSE: C). Here’s a look at how these companies performed in the second quarter:
JPMorgan
JPMorgan delivered reported net revenue of $50.2 billion for Q2 2024, up 22% from the same period a year ago. Managed net revenue increased 20% to $51 billion. Net income increased 25% to $18.1 billion while EPS grew 29% to $6.12. Adjusted EPS was $4.40. JPMorgan beat expectations on both revenue and earnings.
Net interest income grew 4% to $22.9 billion. Non-interest revenue rose 37% to $28.1 billion. Non-interest expense was up 14% to $23.7 billion. Provision for credit losses was up 5% to $3 billion.
CEO Jamie Dimon provided a cautious outlook on the economy. He stated that,
“While market valuations and credit spreads seem to reflect a rather benign economic outlook, we continue to be vigilant about potential tail risks. These tail risks are the same ones that we have mentioned before. The geopolitical situation remains complex and potentially the most dangerous since World War II — though its outcome and effect on the global economy remain unknown. Next, there has been some progress bringing inflation down, but there are still multiple inflationary forces in front of us: large fiscal deficits, infrastructure needs, restructuring of trade and remilitarization of the world. Therefore, inflation and interest rates may stay higher than the market expects.”
Wells Fargo
In Q2 2024, Wells Fargo’s total revenue rose 1% year-over-year to $20.7 billion, beating expectations of $20.2 billion. Net income dipped 1% to $4.9 billion. EPS grew 6% to $1.33, surpassing projections of $1.28.
Net interest income decreased 9% to $11.9 billion. Non-interest income increased 19% to $8.7 billion. Non-interest expense increased 2% to $13.2 billion.
“We continued to see growth in our fee-based revenue offsetting an expected decline in net interest income. The investments we have been making allowed us to take advantage of the market activity in the quarter with strong performance in investment advisory, trading, and investment banking fees. Credit performance was consistent with our expectations, commercial loan demand remained tepid, we saw growth in deposit balances in all of our businesses, and the pace of customers reallocating cash into higher yielding alternatives slowed.” – Charlie Scharf, CEO
Citigroup
Citigroup reported revenues of $20.1 billion for Q2 2024, up 4% year-over-year. Revenues were in line with market estimates. Net income increased 10% to $3.22 billion. EPS rose 14% to $1.52, beating projections.
Citigroup’s end-of-period loans were $688 billion at quarter-end, up 4% versus last year, largely reflecting growth in cards in US Personal Banking and higher loans in Markets and Services. End-of-period deposits were approx. $1.3 trillion at quarter-end, down 3% versus the previous year, mainly due to a reduction in Treasury and Trade Solutions, reflecting quantitative tightening.
“Services continued to grow, driven by solid fee growth increased activity in cross border payments and new client onboardings. Markets had a strong finish to the quarter leading to better performance than we had anticipated. Fixed Income was slightly down year-over-year and Equities was up 37%, driven by strong performance in derivatives. Banking was up 38% as the wallet rebound gained some momentum and we again grew share. Wealth is starting to improve. Growth in client investment assets drove stronger investment revenue, and our focus on rationalizing the expense base is starting to pay off. U.S. Personal Banking saw revenue growth of 6%, with all three businesses again contributing to the topline.” – Jane Fraser, CEO
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on